Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
Apotex Moves From Family To Private Equity, Among Other Transactions
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.
